Effects of chemotherapy on placental development and function using in vitro culture of human primary cytotrophoblasts Christophe Louis DepoixArthur ColsonFrederic Debieve PRECLINICAL STUDIES 03 June 2019 Pages: 547 - 557
Novel thiosemicarbazones induce high toxicity in estrogen-receptor-positive breast cancer cells (MCF7) and exacerbate cisplatin effectiveness in triple-negative breast (MDA-MB231) and lung adenocarcinoma (A549) cells Estefany Ingrid Medina-ReyesMarco Antonio Mancera-RodríguezFelipe Vaca-Paniagua PRECLINICAL STUDIES 08 June 2019 Pages: 558 - 573
The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid Agnieszka KarbownikKatarzyna SobańskaEdyta Szałek PRECLINICAL STUDIES Open access 08 June 2019 Pages: 574 - 583
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells Jelena DinićCarla Ríos-LuciJosé M. Padrón PRECLINICAL STUDIES 08 June 2019 Pages: 584 - 598
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma Yanrong LiKai WangJingdong Zhang PRECLINICAL STUDIES 08 June 2019 Pages: 599 - 609
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms Xing HaoWen XingYuan Zhou PRECLINICAL STUDIES 22 June 2019 Pages: 610 - 620
Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanoma Sotiris KyriakouMelina MitsiogianniMihalis I. Panayiotidis PRECLINICAL STUDIES Open access 26 June 2019 Pages: 621 - 633
Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells Maria Chiara ProtoDonatella FioreSilvia Franceschelli PRECLINICAL STUDIES 26 June 2019 Pages: 634 - 649
Vitamin K3 thio-derivative: a novel specific apoptotic inducer in the doxorubicin-sensitive and -resistant cancer cells Mohamed-Elamir F. HegazyMasashi FukayaThomas Efferth PRECLINICAL STUDIES 29 June 2019 Pages: 650 - 661
Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy Luana Mota FerreiraMarcel Henrique Marcondes SariLetícia Cruz PRECLINICAL STUDIES 02 July 2019 Pages: 662 - 674
In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101 Laura MasuelliMonica BenvenutoRoberto Bei PRECLINICAL STUDIES 02 July 2019 Pages: 675 - 689
Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma Lucy SwiftChunfen ZhangAru Narendran PRECLINICAL STUDIES 02 July 2019 Pages: 690 - 699
A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction Mohammadali Soleimani DamanehJian-Ping HuYing-Qing Wang PRECLINICAL STUDIES 03 July 2019 Pages: 700 - 713
LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancer Yong TangGuojun CaoQi Qin PRECLINICAL STUDIES 03 July 2019 Pages: 714 - 721
T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting Xin SunYang YuMan Zhang PRECLINICAL STUDIES 03 July 2019 Pages: 722 - 732
Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells João Agostinho Machado-NetoJuan Luiz Coelho-SilvaFabiola Traina PRECLINICAL STUDIES 08 July 2019 Pages: 733 - 745
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists Laura Muñoz-MorenoMaría J. CarmenaAna M. Bajo PRECLINICAL STUDIES 17 July 2019 Pages: 746 - 754
Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug Jingkao ChenBingling LuoRongbiao Pi PRECLINICAL STUDIES 14 August 2019 Pages: 755 - 764
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors Mingxiang LiaoSimon WatkinsJim J. Xiao PHASE I STUDIES Open access 27 June 2019 Pages: 765 - 775
Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study Vladimir J. LozanovskiGeorgios PolychronidisIngrid Herr PHASE I STUDIES Open access 27 June 2019 Pages: 776 - 784
Targeting ROS overgeneration by N-benzyl-2-nitro-1-imidazole-acetamide as a potential therapeutic reposition approach for cancer therapy Rodrigo C. ZeferinoNádia S. R. S. MotaRozangela C. Pedrosa PHASE I STUDIES 01 July 2019 Pages: 785 - 799
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma Marcus NoelEileen M. O’ReillyMaeve A. Lowery PHASE I STUDIES Open access 12 July 2019 Pages: 800 - 811
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study Su Young JungSunjin HwangJangik I. Lee PHASE I STUDIES 13 July 2019 Pages: 812 - 820
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer S. Lindsey DavisDana B. CardinSteven J. Cohen PHASE I STUDIES Open access 23 July 2019 Pages: 821 - 830
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma W. Larry GluckMrinal M. GounderHaby A. Henary PHASE I STUDIES Open access 29 July 2019 Pages: 831 - 843
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma Shahneen SandhuCatriona M. McNeilJeffrey R. Infante PHASE I STUDIES 05 August 2019 Pages: 844 - 854
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors Mark N. SteinSusan GoodinJanice M. Mehnert PHASE I STUDIES 06 August 2019 Pages: 855 - 865
A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy Byeong Seok SohnJae Ho JeongSung-Bae Kim PHASE II STUDIES 15 November 2019 Pages: 866 - 873
Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer Weiwei TanNagdeep GiriKourosh Parivar PHASE II STUDIES 19 December 2019 Pages: 874 - 884
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors Taihei OnoSatoshi IgawaKatsuhiko Naoki PHASE III STUDIES 10 March 2020 Pages: 885 - 893
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer Nikita M. VolkovGrigoriy A. YanusEvgeny N. Imyanitov SHORT REPORT 03 August 2019 Pages: 894 - 898
Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours Bárbara dos Santos PassaiaKeli LimaClaudimara Ferini Pacicco Lotfi SHORT REPORT 22 August 2019 Pages: 899 - 908